An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
Phase of Trial: Phase IV
Latest Information Update: 29 Apr 2017
At a glance
- Drugs Pasireotide (Primary)
- Indications Carcinoid tumour; Meningioma; Neuroendocrine tumours; Pituitary cancer; Prostate cancer; Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 04 Aug 2016 Planned number of patients changed from 220 to 400.
- 07 Jan 2016 Planned End Date changed from 1 Apr 2023 to 1 Jul 2024 as reported by ClinicalTrials.gov record.
- 07 Jan 2016 Planned primary completion date changed from 1 Apr 2023 to 1 Jul 2024 as reported by ClinicalTrials.gov record.